Medincell SA
PAR:MEDCL

Watchlist Manager
Medincell SA Logo
Medincell SA
PAR:MEDCL
Watchlist
Price: 14 EUR -1.55% Market Closed
Market Cap: 463m EUR
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one MEDCL stock under the Base Case scenario is hidden EUR. Compared to the current market price of 14 EUR, Medincell SA is hidden .

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

MEDCL Relative Value
HIDDEN
Show
Worst Case
Base Case
Best Case

Valuation Multiples

43.4
P/S
P/S
Price to Sales
43.4
vs History
44
vs Industry
5
Median 3Y
33
Median 5Y
43.6
Industry
2.4
Forward
14.7
More Details
Negative
P/E
P/E
Price to Earnings
N/A
vs History
vs Industry
Median 3Y
-10.1
Median 5Y
-11.6
Industry
20.8
Forward
-14.6
More Details
21.6
P/OCF
P/OCF
Price to OCF
21.6
vs History
7
vs Industry
19
Median 3Y
-10.2
Median 5Y
-14
Industry
15.4
More Details
43.5
P/FCFE
P/FCFE
Price to FCFE
43.5
vs History
7
vs Industry
12
Median 3Y
-10.5
Median 5Y
-15.1
Industry
22.8
More Details
Negative
P/B
P/B
Price to Book Value
N/A
vs History
vs Industry
Median 3Y
-9.6
Median 5Y
-11.4
Industry
2
More Details
44.6
EV/S
EV/S
Enterprise Value to Sales
44.6
vs History
38
vs Industry
5
Median 3Y
36
Median 5Y
42.2
Industry
2.5
Forward
15.1
More Details
48.7
EV/GP
EV/GP
Enterprise Value to Gross Profit
48.7
vs History
57
vs Industry
4
Median 3Y
49.6
Median 5Y
51.9
Industry
4.9
More Details
Negative
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
N/A
vs History
vs Industry
Median 3Y
-13.5
Median 5Y
-16.1
Industry
12.7
Forward
-52.7
More Details
Negative
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
N/A
vs History
vs Industry
Median 3Y
-12.5
Median 5Y
-14.9
Industry
15.8
Forward
-50.8
More Details
22.3
EV/OCF
EV/OCF
Enterprise Value to OCF
22.3
vs History
7
vs Industry
18
Median 3Y
-10.8
Median 5Y
-14.4
Industry
14
More Details
23.7
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
23.7
vs History
7
vs Industry
19
Median 3Y
-10.3
Median 5Y
-13.7
Industry
18.3
More Details
27
EV/IC
EV/IC
Enterprise Value to IC
27
vs History
33
vs Industry
4
Median 3Y
15.7
Median 5Y
21.4
Industry
1.7
More Details

Multiples Across Competitors

MEDCL Competitors Multiples
Medincell SA Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
FR
Medincell SA
PAR:MEDCL
463m EUR 43.4 -14.7 -26.7 -24.4
US
Eli Lilly and Co
NYSE:LLY
775.3B USD 17.2 73.2 42.6 47
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
373.9B USD 4.2 26.6 12.5 16.4
DK
Novo Nordisk A/S
CSE:NOVO B
2.1T DKK 7.1 20.5 13.5 15.4
CH
Roche Holding AG
SIX:ROG
228.6B CHF 3.9 19.9 11.1 13.2
UK
AstraZeneca PLC
LSE:AZN
174.1B GBP 4.2 32.3 127.9 195.3
CH
Novartis AG
SIX:NOVN
196B CHF 4.3 18.7 11.3 14.5
US
Merck & Co Inc
NYSE:MRK
219.3B USD 3.4 12.8 8.7 10.2
IE
Endo International PLC
LSE:0Y5F
167.6B USD 72.3 -57.3 267.5 670.8
US
Pfizer Inc
NYSE:PFE
140B USD 2.2 17.4 8.4 12
P/E Multiple
Earnings Growth PEG
FR
Medincell SA
PAR:MEDCL
Average P/E: 27.7
Negative Multiple: -14.7 		N/A N/A
US
Eli Lilly and Co
NYSE:LLY
73.2
49%
1.5
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
26.6
26%
1
DK
Novo Nordisk A/S
CSE:NOVO B
20.5
19%
1.1
CH
Roche Holding AG
SIX:ROG
19.9
16%
1.2
UK
AstraZeneca PLC
LSE:AZN
32.3
36%
0.9
CH
Novartis AG
SIX:NOVN
18.7
16%
1.2
US
Merck & Co Inc
NYSE:MRK
12.8
18%
0.7
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -57.3 N/A N/A
US
Pfizer Inc
NYSE:PFE
17.4
29%
0.6
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
FR
Medincell SA
PAR:MEDCL
Average EV/EBITDA: 435
Negative Multiple: -26.7 		N/A N/A
US
Eli Lilly and Co
NYSE:LLY
42.6
30%
1.4
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
12.5
7%
1.8
DK
Novo Nordisk A/S
CSE:NOVO B
13.5
15%
0.9
CH
Roche Holding AG
SIX:ROG
11.1
8%
1.4
UK
AstraZeneca PLC
LSE:AZN
127.9
9%
14.2
CH
Novartis AG
SIX:NOVN
11.3
5%
2.3
US
Merck & Co Inc
NYSE:MRK
8.7
9%
1
IE
E
Endo International PLC
LSE:0Y5F
267.5
N/A N/A
US
Pfizer Inc
NYSE:PFE
8.4
3%
2.8
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
FR
Medincell SA
PAR:MEDCL
Average EV/EBIT: 1 869.7
Negative Multiple: -24.4 		N/A N/A
US
Eli Lilly and Co
NYSE:LLY
47
33%
1.4
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
16.4
12%
1.4
DK
Novo Nordisk A/S
CSE:NOVO B
15.4
16%
1
CH
Roche Holding AG
SIX:ROG
13.2
9%
1.5
UK
AstraZeneca PLC
LSE:AZN
195.3
21%
9.3
CH
Novartis AG
SIX:NOVN
14.5
8%
1.8
US
Merck & Co Inc
NYSE:MRK
10.2
12%
0.9
IE
E
Endo International PLC
LSE:0Y5F
670.8
N/A N/A
US
Pfizer Inc
NYSE:PFE
12
10%
1.2

See Also

Summary
MEDCL intrinsic value, competitors valuation, and company profile.
DCF Valuation
MEDCL stock valuation using Discount Cash Flow valuation method.
Relative Valuation
MEDCL stock valuation using valuation multiples.
Wall Street Estimates
MEDCL price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
MEDCL stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 243,300+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.